NNE Pharmaplan
NNE Pharmaplan is the world?s leading engineering and consulting company in the complex field of pharma and biotech. We cover all segments from biopharmaceuticals and vaccines to medical devices and help our customers develop, establish and improve their product manufacturing.
NNE Pharmaplan is the world’s leading engineering and consulting company in the complex field of pharma and biotech. We cover all segments from biopharmaceuticals and vaccines to medical devices and help our customers develop, establish and improve their product manufacturing.
Our customers work with us because we are born out of their industry. For more than 80 years, we have matched technical knowledge with industry experience and worked out simple or complex solutions according to our customers’ needs.
Our reason for being is “Engineering for a healthier world”. We cannot claim to save lives or cure diseases. We do not produce any medicine, but we put all our engineering and consulting capabilities behind the companies that do – our customers. When we deliver consultancy or projects, we help bringing products faster to market, decreasing the overall cost of production and ensuring patient safety.
NNE Pharmaplan employs 1,700 people at more than 30 locations around the world – spanning Europe, Asia and the Americas.
Contact information
NNE Pharmaplan
Corporate head office
Nybrovej 80
2820 Gentofte
Denmark
Email: contact@nnepharmaplan
Web: ref="http://www.nnepharmaplan.com" target="_blank">www.nnepharmaplan.com
Phone: +45 4444 7777
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
